DBV Technologies to Present at Upcoming Investor Conferences
02 Setembro 2022 - 5:30PM
Montrouge, France, September 2, 2022
DBV Technologies to
Present at Upcoming Investor
Conferences
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that Daniel Tassé, Chief
Executive Officer, DBV Technologies, will participate in upcoming
investor conferences in September.
Wells Fargo Healthcare
ConferenceSeptember 7 – 9, 2022 | In-Person Conference |
Boston, MADaniel Tassé will be on-site in Boston on Thursday,
September 8, 2022 to participate in a fireside chat at 4:20 p.m.
ET.
H.C. Wainwright
24rd
Annual Global Investment ConferenceSeptember 12 –
14, 2022 | Hybrid In-Person and Virtual Conference | New York,
NYDaniel Tassé will be on-site in New York on Monday, September 12,
2022 for a company presentation at 11:00 a.m. ET.
A webcast of each engagement, the fireside chat
and company presentation, will be available on the Investors &
Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/.
A replay of both engagements will also be
available on DBV Technologies’ website after the events
conclude.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France, and North American operations in Basking Ridge, NJ. The
Company’s ordinary shares are traded on segment B of Euronext Paris
(Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs
(each representing one-half of one ordinary share) are traded on
the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393
angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
